06/05/2016 03:25:54 1-888-992-3836 (toll free) Free Membership Login

Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
05/04/20168:00AMGLOBEInovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Societ...
PLYMOUTH MEETING, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it will exhibit the breadth and promise of its cancer and infectious disease immunotherapy, vaccine and DNA-based monoclonal antibody (dMAb) pipeline in 10 presentations at the 19th Annual Meeting of the American... More...>>
05/02/20167:31AMGLOBEInovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology
PLYMOUTH MEETING, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.’s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, which it first announced... More...>>
04/28/201611:46AMGLOBEInovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial
PLYMOUTH MEETING, Pa., April 27, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments. The study will enroll patients... More...>>
04/28/201611:46AMGLOBEInovio Pharmaceuticals to Report First Quarter 2016 Financial Results May 9, 2016
PLYMOUTH MEETING, Pa., April 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2016 first quarter financial results on Monday, May 9, 2016 at 8:30 a.m. ET. A live and archived version of the audio presentation will be... More...>>
03/30/20169:40AMGLOBEInovio Ebola Vaccine Generates Robust Immune Responses in Humans
PLYMOUTH MEETING, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its fully enrolled phase I study of 75 healthy subjects. Detailed immunogenicity and safety data... More...>>
03/30/20168:00AMGLOBEInovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress
PLYMOUTH MEETING, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its immunotherapy to treat cervical dysplasia (VGX-3100) was recognized as "Best Therapeutic Vaccine" by the World Vaccine Congress held this week in Washington, D.C. The Vaccine Industry Excellence... More...>>
03/29/20168:00AMGLOBEInovio Updates INO-3112 HPV Immunotherapy Development Plan
PLYMOUTH MEETING, Pa., March 29, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical strategy update to take its INO-3112 HPV immunotherapy into human studies in combination with selected immunotherapy molecules from MedImmune, the global biologics research & development arm... More...>>
03/22/20166:55AMGLOBEInovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge i...
PLYMOUTH MEETING, Pa., March 22, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its novel dMAb antibody and DNA vaccine targeting the chikungunya virus (CHIKV) provided 100% protection against a lethal virus challenge in mice. This breakthrough data was published in the latest issue... More...>>
03/16/20167:00AMGLOBEInovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and Vaccines
New Agreement Follows Dr. David B. Weiner’s Move to Wistar from the University of Pennsylvania (UPenn)  Inovio will maintain all existing license agreements with UPenn PLYMOUTH MEETING, Pa., March 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has signed collaborative research... More...>>
03/14/20168:00AMGLOBEInovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines
PLYMOUTH MEETING, Pa., March 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has signed a definitive agreement to acquire all of Bioject Medical Technologies Inc.’s assets including pioneering needle-free jet injection technology, devices, and intellectual property. Inovio will... More...>>
03/14/20166:30AMGLOBEInovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2015. Total revenue was $5.9 million and $40.6 million for the quarter and year ended December 31, 2015, as compared to $2.5 million and... More...>>
03/11/20168:00AMGLOBEInovio Pharmaceuticals Appoints DNA Immunotherapy Pioneer David B. Weiner, Ph.D., to its Board of Directors
PLYMOUTH MEETING, Pa., March 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that David B. Weiner, Ph.D., recognized in scientific circles as the “father of DNA vaccines and immunotherapies,” has been appointed to Inovio’s Board of Directors. Dr. Weiner was co-founder with J... More...>>
03/09/20167:46PMGLOBEInovio Pharmaceuticals to Report Fourth Quarter and Year End 2015 Financial Results on March 14, 2016
PLYMOUTH MEETING, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2015 fourth quarter and year-end financial results on Monday, March 14, 2016 at 8:30 a.m. ET.  A live and archived version of the audio... More...>>
03/06/20167:43PMDJNDrugmakers Scramble to Find Zika Vaccine
By Betsy McKay and Peter Loftus International health officials vowed after West Africa's Ebola crisis to be better armed for the next epidemic with vaccines, drugs and diagnostic tests. Now the next one--Zika--is here and in an echo of Ebola, researchers are scrambling to develop medical tools to fight the virus... More...>>
02/17/20167:00AMGLOBEInovio Pharmaceutical's DNA Vaccine for Zika Virus Induces Robust Immune Responses in Preclinical Study
Biotech begins clinical manufacturing; expects to test Zika vaccine in humans in 2016 PLYMOUTH MEETING, Pa., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses... More...>>
02/02/20168:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that management will participate at three upcoming investor conferences in February: BIO CEO & Investor ConferenceFebruary 8-9, 2016New York, NYRBC Capital Markets Global Healthcare ConferenceFebruary... More...>>
01/28/20167:00AMGLOBEInovio Pharmaceuticals and GeneOne Life Science Initiate Patient Recruitment for MERS Vaccine Trial
PLYMOUTH MEETING, Pa., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the beginning of recruitment for its collaborative vaccine study for MERS (Middle East Respiratory Syndrome). Inovio and GeneOne Life Science Inc. (KSE:011000) are co-developing Inovio’s MERS vaccine (GLS-5300... More...>>
01/22/20165:00AMGLOBEGeneOne Life Science and Inovio Pharmaceuticals to Collaborate on Zika Virus Vaccine Development
SEOUL, South Korea, Jan. 22, 2016 (GLOBE NEWSWIRE) -- GeneOne Life Science (KSE:011000) today announced the initiation of a collaborative research program with Inovio Pharmaceuticals (NASDAQ:INO) to test and advance a DNA-based vaccine for preventing and treating the emerging and virulent Zika virus infection.   Inovio... More...>>
01/19/20168:00AMGLOBEInovio Pharmaceuticals Awarded Grant to Advance Needle-Free Vaccine Delivery Device
PLYMOUTH MEETING, Pa., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has been selected to receive a $500,000 grant from the U.S. Army’s Small Business Innovation Research (SBIR) program to further advance the development of Inovio’s next generation delivery device capable... More...>>
01/05/20168:00AMGLOBEInovio Pharmaceuticals to Present at Biotech Showcase
PLYMOUTH MEETING, Pa., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will give a corporate presentation on Tuesday, January 12th at 9:30AM PST at Biotech Showcase 2016. Dr. Kim will also participate on a Biotech Showcase panel entitled... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20160506 07:25:56